PHILADELPHIA, May 5, 2020 /PRNewswire/ -- The coronavirus pandemic has significantly disrupted life in most countries around the globe, causing a severe health and economic crisis. AUM LifeTech, Inc., a preclinical stage biotech company developing RNA therapeutics, and AUM BioTech, LLC, a genetic research startup, have jointly launched a research program called Knockdown Coronavirus with a goal of developing a treatment for COVID-19. Under this initiative, the two Philadelphia-based companies are offering self-delivering RNA silencing research products, powered by FANA ASO technology, to the global coronavirus research community to facilitate research and fast track therapeutic development.
AUM LifeTech is currently working with collaborators with the goal of developing a therapy for COVID-19. AUM BioTech's next-generation gene silencing research tools have the capability to selectively knockdown RNA of the virus. Further, AUM BioTech's RNA targeting technology can be used to perform high-throughput genetic screening to identify the function of viral and host genes and help identify new targets for COVID-19 therapy development.
Read more on PRNewswire.
